<?xml version="1.0" encoding="UTF-8"?><urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:image="http://www.google.com/schemas/sitemap-image/1.1"><url><loc>https://insights.citeline.com/medtech-insight/conferences/medcon/medcon-day-2-fda-officials-update-stakeholders-on-new-risk-based-inspection-regime-VDU2IBDYDZDULCC7GHHCLA4WJQ/</loc><lastmod>2026-04-23T23:53:51.169Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><image:image><image:loc>https://insights.citeline.com/resizer/uGAQ6Jj0AXedWbhQsFlPLHNJi6I=/cloudfront-us-east-1.images.arcpublishing.com/norstella/6JV7D7G6XBA4FPZZNBCJLHPALQ.jpg</image:loc></image:image></url><url><loc>https://insights.citeline.com/pink-sheet/market-access/pricing-debate/double-billing-regeneron-mfn-deal-announced-along-with-approval-of-its-gene-therapy-CEMJNLG2FJHNLDF2VXH3PGBEPE/</loc><lastmod>2026-04-23T23:32:45.945Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><image:image><image:loc>https://insights.citeline.com/resizer/riHUNruLLlcT3zW7GzaJE_xgnAw=/cloudfront-us-east-1.images.arcpublishing.com/norstella/42T7HZHBKFEHPOZA6PGBSOCHII.jpg</image:loc><image:caption><![CDATA[Regeneron gets its turn in the Oval Office.]]></image:caption></image:image></url><url><loc>https://insights.citeline.com/medtech-insight/policy-and-regulation/approvals/cms-and-fda-propose-rapid-path-for-faster-reimbursement-7PTWEOIJUJASLJY7JARLKK6CQI/</loc><lastmod>2026-04-23T23:19:15.915Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><image:image><image:loc>https://insights.citeline.com/resizer/J2KuHFPJe2SO5YnwNTUsO4dDGQs=/cloudfront-us-east-1.images.arcpublishing.com/norstella/BGRWMAMT5JDQHIMJBXUE5W45BU.jpg</image:loc><image:caption><![CDATA[The RAPID pathway is CMS and the FDA's latest joint effort to get novel technology to patients more quickly.]]></image:caption></image:image></url><url><loc>https://insights.citeline.com/medtech-insight/business/financing/acuitymd-raises-80m-to-bring-agentic-ai-to-medtech-sales-NJ67ENNITVHARELQCJTEUGMHLU/</loc><lastmod>2026-04-23T22:56:23.893Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><image:image><image:loc>https://insights.citeline.com/resizer/LeNaKTPqVPzaoHBUokcaMsC0hzs=/cloudfront-us-east-1.images.arcpublishing.com/norstella/7MVCNNEWDVGELLFWWNAXEMF7ME.jpg</image:loc><image:caption><![CDATA[AcuityMD, whose medtech sales software serves more than 400 medtech companies, has closed an $80 million Series C round led by StepStone Group.]]></image:caption></image:image></url><url><loc>https://insights.citeline.com/scrip/r-and-d/clinical-trials/merck-and-eisais-keytrudalenvimawelireg-trial-in-kidney-cancer-fails-4Y4GLHJNSNEKJEEHU4DP3SKAWI/</loc><lastmod>2026-04-23T21:46:13.55Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><image:image><image:loc>https://insights.citeline.com/resizer/WxX9Xf9eEgIB2Bb9MbdNKmAlvpk=/cloudfront-us-east-1.images.arcpublishing.com/norstella/UP76E7SA6BEEZI57KMIZNYSS5E.jpg</image:loc><image:caption><![CDATA[Merck and Eisai announced results from the LITESPARK-012 trial, saying that the trial did not meet either of its primary endpoints.]]></image:caption></image:image></url><url><loc>https://insights.citeline.com/scrip/therapeutic-category/cardiovascular/bioage-outlines-clinical-expansion-plans-for-bge-102-G3EBRD5MCRC35FFYPRDOAQNEHQ/</loc><lastmod>2026-04-23T21:45:30.61Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><image:image><image:loc>https://insights.citeline.com/resizer/aukOI4oyRF0xvM8c7mtbbwU9fYQ=/cloudfront-us-east-1.images.arcpublishing.com/norstella/U5JLXIX3IVG2JPOO4JKXGYRNHY.jpg</image:loc></image:image></url><url><loc>https://insights.citeline.com/hbw-insight/wellness/policy-and-regulation/regulation/expanding-otc-choices-in-us-confuse-consumers-while-increasing-out-of-pocket-costs-UYBO7PYWCZD33DJNAQX5EHT7XM/</loc><lastmod>2026-04-23T20:38:55.827Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><image:image><image:loc>https://insights.citeline.com/resizer/F_kYnTpdfMnxDRJXWeXuWjVDVR8=/cloudfront-us-east-1.images.arcpublishing.com/norstella/UJB3UQZB6RAYPCVXZJTYQVT2GQ.jpg</image:loc></image:image></url><url><loc>https://insights.citeline.com/medtech-insight/business/earnings/boston-scientific-adjusts-to-new-pfa-landscape-as-medtronic-jj-and-abbott-take-market-share-SDG2ICCNYVHKXMQEB57NB5ICSM/</loc><lastmod>2026-04-23T19:45:47.302Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><image:image><image:loc>https://insights.citeline.com/resizer/zsHT6KAmS8zUuodZpMKyx-RspLY=/cloudfront-us-east-1.images.arcpublishing.com/norstella/QWH4HCMOVRCD5PRHB7NZ7EADDU.jpg</image:loc><image:caption><![CDATA[For the full year of 2026, the company reduced its organic growth guidance to 6.5% to 8and guided to second-quarter organic growth of 5% to 7%. Picture Courtesy: Shutterstock]]></image:caption></image:image></url><url><loc>https://insights.citeline.com/pink-sheet/biosimilars-and-generics/generics/gdufa-iv-industry-could-lower-application-fees-by-raising-program-fees-6IXCSAUL2FHWBCMF5QYXXNEBGU/</loc><lastmod>2026-04-23T16:31:01.458Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><image:image><image:loc>https://insights.citeline.com/resizer/Gv_OElJaTVPupnOv-IzYBA0yC3w=/cloudfront-us-east-1.images.arcpublishing.com/norstella/2X3OLDEYHJE3FGMNQVBWDE6NF4.jpg</image:loc><image:caption><![CDATA[Revenue generated by GDUFA ANDA and program fees would change under an industry proposal.]]></image:caption></image:image></url><url><loc>https://insights.citeline.com/medtech-insight/leadership/execs-on-the-move-april-1317-2026-4RAC54T725BBBOASB6SOBZW45Y/</loc><lastmod>2026-04-23T16:05:54.435Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><image:image><image:loc>https://insights.citeline.com/resizer/h4fVGgwOIyO4RzeYcyFoc_E91Qo=/cloudfront-us-east-1.images.arcpublishing.com/norstella/QSTAM7SGMJOYTGEBU2RZSDKLYA.jpg</image:loc></image:image></url><url><loc>https://insights.citeline.com/pink-sheet/market-access/pricing-debate/germanys-higher-drug-rebates-would-send-the-wrong-message-to-pharma-GHEDMDIBVBATTGOLHEPLJUANHM/</loc><lastmod>2026-04-23T15:59:04.687Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><image:image><image:loc>https://insights.citeline.com/resizer/5T12wzxKcS2zznZY6r-rHPmVmXo=/cloudfront-us-east-1.images.arcpublishing.com/norstella/GYXRJ2Q3PFGL3MOXOBNJOPF2KE.jpg</image:loc><image:caption><![CDATA[Proposed cost cutting measures would bring more uncertainty for pharmaceutical companies.]]></image:caption></image:image></url><url><loc>https://insights.citeline.com/hbw-insight/wellness/innovationandip/new-products/adding-b-vitamins-to-areds-has-bausch-lomb-seeing-consumer-health-sales-boost-ahead-2VG7Q7GF7FCJVEX4ZPXYL5FR6M/</loc><lastmod>2026-04-23T15:42:04.469Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><image:image><image:loc>https://insights.citeline.com/resizer/4GA2-UcZAaXXfkfWw6BUmBqd_lQ=/cloudfront-us-east-1.images.arcpublishing.com/norstella/V7VXFQ7V25CGJC5VEGWIVCXSFA.jpg</image:loc></image:image></url><url><loc>https://insights.citeline.com/hbw-insight/esg/eus-pfas-in-supplement-packaging-rules-coming-into-force-soon-QLGLHRT65VGNNGPAQGZZDMTQCY/</loc><lastmod>2026-04-23T15:35:19.225Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><image:image><image:loc>https://insights.citeline.com/resizer/q5_8r2uhJcTQ_rU09el5r0sCjQ0=/cloudfront-us-east-1.images.arcpublishing.com/norstella/2ZCZTOYU4ZKQHA4QIOIG7A6YRY.jpg</image:loc></image:image></url><url><loc>https://insights.citeline.com/hbw-insight/leadership/interviews/serving-billions-not-just-selling-products-bayers-consumer-health-strategy-CYKUT6OSRBESFEEHPCWMUNJ5E4/</loc><lastmod>2026-04-23T15:31:04.761Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><image:image><image:loc>https://insights.citeline.com/resizer/XkV2aP8wqv5xqrmyavIIGuk3qSI=/cloudfront-us-east-1.images.arcpublishing.com/norstella/6DP77GHGH5DJHC75SVSIKTEGPI.jpg</image:loc></image:image></url><url><loc>https://insights.citeline.com/hbw-insight/health/business/earnings/reckitt-weighed-down-by-sluggish-cold-flu-season-HVI7WFJTPRCBFCRTYQR75LL5DU/</loc><lastmod>2026-04-23T15:24:49.335Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><image:image><image:loc>https://insights.citeline.com/resizer/NSj7oVDPb_MbYJWpSEnj4YPHGIk=/cloudfront-us-east-1.images.arcpublishing.com/norstella/FS2FJ4KZLFCPNKPHXA7IR45WLU.jpg</image:loc></image:image></url><url><loc>https://insights.citeline.com/pink-sheet/r-and-d/clinical-trials/complex-trials-clash-with-eu-ctis-translation-fix-on-patient-facing-documents-ALQ6CCEFBVG5HBV5YQJVMIQBK4/</loc><lastmod>2026-04-23T15:12:49.567Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><image:image><image:loc>https://insights.citeline.com/resizer/FzymdmHeN0cLCuhyh7eXiaDxk7k=/cloudfront-us-east-1.images.arcpublishing.com/norstella/DKUHOAM4QBGZHDZXZA2O5TSPZ4.jpg</image:loc><image:caption><![CDATA[Sponsors complained about translations being required before EU member state were ready to start trials]]></image:caption></image:image></url><url><loc>https://insights.citeline.com/generics-bulletin/business/deals/amneal-joins-the-biosimilar-a-list-with-1bn-kashiv-buyout-2RIFVT5JPJHR7NZUSX3EDL6FCE/</loc><lastmod>2026-04-23T13:58:15.994Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><image:image><image:loc>https://insights.citeline.com/resizer/f_ugh3922ojlCXrURiUpUaKDgpM=/cloudfront-us-east-1.images.arcpublishing.com/norstella/V6Y6JVCO55AJ7BPMM3TQDIKFGE.jpg</image:loc><image:caption><![CDATA[Amneal is joining a select set of leading vertically-integrated biosimilars firms]]></image:caption></image:image></url><url><loc>https://insights.citeline.com/generics-bulletin/products/generics/cipla-breaks-ventolin-barrier-in-us-generics-LKULZ6GSSZBHXJGE25S5KDZI24/</loc><lastmod>2026-04-23T13:37:21.976Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><image:image><image:loc>https://insights.citeline.com/resizer/bBmP75bbH2a7dBhkHzzBwYUC2Ug=/cloudfront-us-east-1.images.arcpublishing.com/norstella/YO564KM6BJGYDATDDF4HYPD3LI.jpg</image:loc></image:image></url><url><loc>https://insights.citeline.com/generics-bulletin/products/biosimilars/prestige-biopharma-targets-easier-biosimilar-injections-MU32V74VWFESFKBULAWI2SZUWY/</loc><lastmod>2026-04-23T10:30:32.544Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><image:image><image:loc>https://insights.citeline.com/resizer/KTtfFsuoDdc93gYGgANGqK10-Uw=/cloudfront-us-east-1.images.arcpublishing.com/norstella/Z5IQ4KB54NJ2DK47NKQ2W7BQ3M.jpg</image:loc></image:image></url><url><loc>https://insights.citeline.com/medtech-insight/policy-and-regulation/compliance/imdrf-ai-framework-could-alter-cost-of-compliance-NJEZEI7IA5CPVE4I663K3IFE3Q/</loc><lastmod>2026-04-23T10:26:14.543Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><image:image><image:loc>https://insights.citeline.com/resizer/Idfv3I00i7jPoKTgLZZIKI5WKZY=/cloudfront-us-east-1.images.arcpublishing.com/norstella/W6DZ5O7T3FB75DXRTT3A7W6TU4.jpg</image:loc><image:caption><![CDATA[In an attempt to resolve the governance gap, the International Medical Device Regulators Forum (IMDRF) recently released a draft framework on how AI can be safely incorporated in healthcare devices. ]]></image:caption></image:image></url><url><loc>https://insights.citeline.com/hbw-insight/beauty/policy-and-regulation/qa-with-dsm-firmenich-on-parsol-shields-expected-impact-on-us-market-WVMHFVXYWFB6ZHCLZFNHBMFDLY/</loc><lastmod>2026-04-23T10:02:52.188Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><image:image><image:loc>https://insights.citeline.com/resizer/9F7bGyotii8oszC2af9N_JmWsQE=/cloudfront-us-east-1.images.arcpublishing.com/norstella/NTL5IBEOTJHSFI4B25I6BCS7QY.jpg</image:loc><image:caption><![CDATA[US FDA's proposed order to add DSM-Firmenich's bemotrizinol UV filter, known commercially as PARSOL Shield, to the sunscreen monograph 'meaningfully expands the sunscreen formulator’s toolbox,' says company.]]></image:caption></image:image></url><url><loc>https://insights.citeline.com/pink-sheet/pathways-and-standards/india-must-institutionalize-risk-based-inspections-harness-ai-for-pharmacovigilance-says-panel-JYLQLZ5C25ELFHQIYP5MUSH5KQ/</loc><lastmod>2026-04-23T08:51:19.112Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><image:image><image:loc>https://insights.citeline.com/resizer/eZ6pS5epsJ0xY4YJz6LY6UXsuuM=/cloudfront-us-east-1.images.arcpublishing.com/norstella/LTJ6E572OZFCVJXLSO5K7O7G2M.jpg</image:loc><image:caption><![CDATA[Parliamentary panel makes recommendations on key aspects of India’s drug regulatory system]]></image:caption></image:image></url><url><loc>https://insights.citeline.com/pink-sheet/policy-regulation/iran-war-exposes-weaknesses-in-pharma-resilience-planning-4GE6OKSHV5B5HMEKPKYW4XMW4U/</loc><lastmod>2026-04-23T08:06:57.746Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><image:image><image:loc>https://insights.citeline.com/resizer/Ln63XBY_TCgXiQmMKS8_cJaxnhw=/cloudfront-us-east-1.images.arcpublishing.com/norstella/EDB3OCKQKFFXNCYIPLTXDGYZUY.jpg</image:loc><image:caption><![CDATA[Pharmaceutical companies must reprioritize resilience planning to better cope with shocks like the Iran war.]]></image:caption></image:image></url><url><loc>https://insights.citeline.com/pink-sheet/sandoz-builds-new-model-for-african-drug-access-6LIZTU2XZVCZBLDOGKMQHBJQPY/</loc><lastmod>2026-04-23T08:05:40.133Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><image:image><image:loc>https://insights.citeline.com/resizer/t_9iEHCwRrP3Xq2eIY6J6nLdXBw=/cloudfront-us-east-1.images.arcpublishing.com/norstella/AYWGEWI3FVPLZJ5S364BSXHNGA.jpg</image:loc><image:caption><![CDATA[Sandoz’s procurement model for Africa bypasses fragmented purchasing systems]]></image:caption></image:image></url><url><loc>https://insights.citeline.com/pink-sheet/product-reviews/complete-response-letters/drug-industry-escalates-fight-over-us-fda-crl-disclosures-seeks-redaction-role-OWFUTNDHVRFQ7DLQ4EVOMVNDPA/</loc><lastmod>2026-04-23T08:04:02.076Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><image:image><image:loc>https://insights.citeline.com/resizer/jrcaGB1_SOxp_20Fb8LSA_vAPaY=/cloudfront-us-east-1.images.arcpublishing.com/norstella/UUIERV25C5CFRD6G6BL2PTSPOY.jpg</image:loc><image:caption><![CDATA[Industry is seeking procedural protections before FDA releases CRLs tied to unapproved applications.]]></image:caption></image:image></url><url><loc>https://insights.citeline.com/pink-sheet/rare-diseases/data-sharing-financial-incentives-needed-but-plausible-mechanism-is-a-catalyst-QMJ7JJ5SWNGBVKBZCNFBJLDXZQ/</loc><lastmod>2026-04-23T08:03:24.107Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><image:image><image:loc>https://insights.citeline.com/resizer/qIF0MmCRoWRyf-Isvh8UVIMWRjA=/cloudfront-us-east-1.images.arcpublishing.com/norstella/MM2B5GR75RDQFMCPD2TC3SEN4U.jpg</image:loc><image:caption><![CDATA[Financial incentives would help encourage data-sharing agreements.]]></image:caption></image:image></url><url><loc>https://insights.citeline.com/generics-bulletin/balance-model-delay-may-lead-to-revisions-higher-near-term-medicare-costs-B4LSH6CVIVGNRIPNVL5JIOR7YQ/</loc><lastmod>2026-04-23T08:02:34.701Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><image:image><image:loc>https://insights.citeline.com/resizer/8Bc-QR8-PBB_u1TPiqlw-2adyos=/cloudfront-us-east-1.images.arcpublishing.com/norstella/JCLPB4PCYFDR7BBMJTR4ZWBCGQ.jpg</image:loc><image:caption><![CDATA[CMS backing off 2027 launch of obesity drug payment demonstration in Part D.]]></image:caption></image:image></url><url><loc>https://insights.citeline.com/scrip/leadership/interviews/alphamab-pursues-differentiated-approach-to-next-gen-adcs-455SCBRW4JFKNB2PVPAHV473XU/</loc><lastmod>2026-04-23T07:51:02.314Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><image:image><image:loc>https://insights.citeline.com/resizer/xeq8jcfHKag1S_VbRMt51dKCKSg=/cloudfront-us-east-1.images.arcpublishing.com/norstella/N4JB2T4W4NMX3C22VRPXSTJGYE.jpg</image:loc><image:caption><![CDATA[The discovery and development space for ADCs and multispecific antibodies have just opened up. ]]></image:caption></image:image></url><url><loc>https://insights.citeline.com/scrip/conferences/aacr-chinese-firms-present-first-in-class-multispecific-adc-tce-contenders-NHJUY2PIFVFRXLSRC5Y3IN5RQY/</loc><lastmod>2026-04-23T07:23:31.338Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><image:image><image:loc>https://insights.citeline.com/resizer/-_Xcm-rgemItEKGrAdtjWn5YhIY=/cloudfront-us-east-1.images.arcpublishing.com/norstella/DWXX5AXVUVJ7TGIZK2NYTHIISU.jpg</image:loc><image:caption><![CDATA[The 2026 AACR was held in San Diego, California over April 17-22. ]]></image:caption></image:image></url><url><loc>https://insights.citeline.com/medtech-insight/device-area/gastroenterology/feeding-pump-that-grew-from-a-fathers-mission-receives-fda-clearance-GRDXHB2L3NF6ZNCGHNA4KNI4AU/</loc><lastmod>2026-04-23T01:33:36.688Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><image:image><image:loc>https://insights.citeline.com/resizer/xZap5TuoeWhLyw-yNNx1o6oKv6U=/cloudfront-us-east-1.images.arcpublishing.com/norstella/S2FCIAIEGJGE7F47IM4G322BEM.png</image:loc><image:caption><![CDATA[Luminoah will introduce its Flow enteral nutrition pump at three health systems after receiving FDA clearance.]]></image:caption></image:image></url><url><loc>https://insights.citeline.com/companies/apsen-farmaceutica-sa/</loc><lastmod>2026-04-23T00:05:16.673Z</lastmod><changefreq>always</changefreq><priority>0.5</priority></url><url><loc>https://insights.citeline.com/companies/jiksak-bioengineering-inc/</loc><lastmod>2026-04-23T00:05:10.895Z</lastmod><changefreq>always</changefreq><priority>0.5</priority></url><url><loc>https://insights.citeline.com/companies/oxy5-oncomedical-ag/</loc><lastmod>2026-04-23T00:05:04.667Z</lastmod><changefreq>always</changefreq><priority>0.5</priority></url><url><loc>https://insights.citeline.com/companies/foshan-ruidio-pharmaceutical-co-ltd/</loc><lastmod>2026-04-23T00:04:58.483Z</lastmod><changefreq>always</changefreq><priority>0.5</priority></url><url><loc>https://insights.citeline.com/companies/beijing-jiluntai-pharmaceutical-co-ltd/</loc><lastmod>2026-04-23T00:04:52.443Z</lastmod><changefreq>always</changefreq><priority>0.5</priority></url><url><loc>https://insights.citeline.com/companies/stratum-biosciences</loc><lastmod>2026-04-23T00:04:46.662Z</lastmod><changefreq>always</changefreq><priority>0.5</priority></url><url><loc>https://insights.citeline.com/companies/feromics-inc/</loc><lastmod>2026-04-23T00:04:40.634Z</lastmod><changefreq>always</changefreq><priority>0.5</priority></url><url><loc>https://insights.citeline.com/companies/zhejiang-fonow-medicine-co-ltd/</loc><lastmod>2026-04-23T00:04:34.579Z</lastmod><changefreq>always</changefreq><priority>0.5</priority></url><url><loc>https://insights.citeline.com/companies/galenika/</loc><lastmod>2026-04-23T00:04:28.573Z</lastmod><changefreq>always</changefreq><priority>0.5</priority></url><url><loc>https://insights.citeline.com/companies/wuhan-kadwise-biotechnology-co-ltd/</loc><lastmod>2026-04-23T00:04:22.429Z</lastmod><changefreq>always</changefreq><priority>0.5</priority></url><url><loc>https://insights.citeline.com/companies/virchow-medical-inc/</loc><lastmod>2026-04-23T00:04:16.588Z</lastmod><changefreq>always</changefreq><priority>0.5</priority></url><url><loc>https://insights.citeline.com/companies/icura-diagnostics-inc</loc><lastmod>2026-04-23T00:04:10.387Z</lastmod><changefreq>always</changefreq><priority>0.5</priority></url><url><loc>https://insights.citeline.com/companies/seismic-pharmaceuticals</loc><lastmod>2026-04-23T00:04:04.292Z</lastmod><changefreq>always</changefreq><priority>0.5</priority></url><url><loc>https://insights.citeline.com/companies/ribopeutic</loc><lastmod>2026-04-23T00:03:58.542Z</lastmod><changefreq>always</changefreq><priority>0.5</priority></url><url><loc>https://insights.citeline.com/companies/papillon-therapeutics</loc><lastmod>2026-04-23T00:03:46.228Z</lastmod><changefreq>always</changefreq><priority>0.5</priority></url><url><loc>https://insights.citeline.com/companies/orthogonal-neuroscience</loc><lastmod>2026-04-23T00:03:40.404Z</lastmod><changefreq>always</changefreq><priority>0.5</priority></url><url><loc>https://insights.citeline.com/companies/secarna-pharmaceuticals-gmbh-co-kg</loc><lastmod>2026-04-23T00:03:34.139Z</lastmod><changefreq>always</changefreq><priority>0.5</priority></url><url><loc>https://insights.citeline.com/companies/tenvie-therapeutics</loc><lastmod>2026-04-23T00:03:28.124Z</lastmod><changefreq>always</changefreq><priority>0.5</priority></url><url><loc>https://insights.citeline.com/companies/orlance-inc</loc><lastmod>2026-04-23T00:03:22.093Z</lastmod><changefreq>always</changefreq><priority>0.5</priority></url><url><loc>https://insights.citeline.com/companies/kelonia-therapeutics-inc</loc><lastmod>2026-04-23T00:03:16.192Z</lastmod><changefreq>always</changefreq><priority>0.5</priority></url><url><loc>https://insights.citeline.com/companies/nyra-medical-inc</loc><lastmod>2026-04-23T00:03:10.141Z</lastmod><changefreq>always</changefreq><priority>0.5</priority></url><url><loc>https://insights.citeline.com/companies/theriva-biologics-inc</loc><lastmod>2026-04-23T00:03:04.092Z</lastmod><changefreq>always</changefreq><priority>0.5</priority></url><url><loc>https://insights.citeline.com/companies/expres2ion-biotech-holding-ab</loc><lastmod>2026-04-23T00:02:58.108Z</lastmod><changefreq>always</changefreq><priority>0.5</priority></url><url><loc>https://insights.citeline.com/companies/bone-biologics-corp</loc><lastmod>2026-04-23T00:02:52.061Z</lastmod><changefreq>always</changefreq><priority>0.5</priority></url><url><loc>https://insights.citeline.com/companies/vivos-inc</loc><lastmod>2026-04-23T00:02:46.036Z</lastmod><changefreq>always</changefreq><priority>0.5</priority></url><url><loc>https://insights.citeline.com/companies/modular-medical</loc><lastmod>2026-04-23T00:02:39.899Z</lastmod><changefreq>always</changefreq><priority>0.5</priority></url><url><loc>https://insights.citeline.com/companies/medpace-inc</loc><lastmod>2026-04-23T00:02:33.984Z</lastmod><changefreq>always</changefreq><priority>0.5</priority></url><url><loc>https://insights.citeline.com/companies/tactiva-therapeutics</loc><lastmod>2026-04-23T00:02:28.075Z</lastmod><changefreq>always</changefreq><priority>0.5</priority></url><url><loc>https://insights.citeline.com/companies/lotus-pharmaceutical-co-ltd</loc><lastmod>2026-04-23T00:02:21.879Z</lastmod><changefreq>always</changefreq><priority>0.5</priority></url><url><loc>https://insights.citeline.com/companies/university-of-sheffield</loc><lastmod>2026-04-23T00:02:15.995Z</lastmod><changefreq>always</changefreq><priority>0.5</priority></url><url><loc>https://insights.citeline.com/companies/dizal-jiangsu-pharmaceutical-co-ltd</loc><lastmod>2026-04-23T00:02:09.719Z</lastmod><changefreq>always</changefreq><priority>0.5</priority></url><url><loc>https://insights.citeline.com/companies/shanghai-perhum-therapeutics-co-ltd</loc><lastmod>2026-04-23T00:02:03.796Z</lastmod><changefreq>always</changefreq><priority>0.5</priority></url><url><loc>https://insights.citeline.com/companies/algernon-health</loc><lastmod>2026-04-23T00:01:57.741Z</lastmod><changefreq>always</changefreq><priority>0.5</priority></url><url><loc>https://insights.citeline.com/companies/biodexa-pharmaceuticals-plc</loc><lastmod>2026-04-23T00:01:52.388Z</lastmod><changefreq>always</changefreq><priority>0.5</priority></url><url><loc>https://insights.citeline.com/companies/biotest-gmbh-co-kgaa/</loc><lastmod>2026-04-23T00:01:48.559Z</lastmod><changefreq>always</changefreq><priority>0.5</priority></url><url><loc>https://insights.citeline.com/companies/nxera-pharma-co-ltd</loc><lastmod>2026-04-23T00:01:45.745Z</lastmod><changefreq>always</changefreq><priority>0.5</priority></url><url><loc>https://insights.citeline.com/companies/orphan-therapeutics-llc</loc><lastmod>2026-04-23T00:01:39.497Z</lastmod><changefreq>always</changefreq><priority>0.5</priority></url><url><loc>https://insights.citeline.com/companies/yichang-humanwell-pharmaceutical-co-ltd</loc><lastmod>2026-04-23T00:01:33.755Z</lastmod><changefreq>always</changefreq><priority>0.5</priority></url><url><loc>https://insights.citeline.com/companies/trevena-inc</loc><lastmod>2026-04-23T00:01:27.623Z</lastmod><changefreq>always</changefreq><priority>0.5</priority></url><url><loc>https://insights.citeline.com/companies/biovie-inc</loc><lastmod>2026-04-23T00:01:21.831Z</lastmod><changefreq>always</changefreq><priority>0.5</priority></url></urlset>